Pegozafermin FGF21 MASH Phase III — PatSnap Eureka
Pegozafermin FGF21 vs. Resmetirom vs. Lanifibranor: The Phase III MASH Race
Three distinct mechanisms. Two regulatory endpoints. One transforming disease area. Explore how Roche/89bio's glycoPEGylated FGF21 analog stacks up against the approved THR-β agonist and the pan-PPAR challenger in the most competitive liver disease pipeline of the decade.
Three Pathways, One Disease: How Each Drug Attacks MASH
MASH (Metabolic dysfunction-Associated SteatoHepatitis) is driven by lipotoxicity, inflammation, and progressive fibrosis. Each of the three leading Phase III candidates targets a distinct node in this pathological cascade, as catalogued in PatSnap's IP analytics platform.
Pegozafermin: GlycoPEGylated FGF21 Analog
Pegozafermin is an engineered analog of fibroblast growth factor 21 (FGF21), a hepatokine that regulates lipid and glucose metabolism. By binding FGF21 receptors (FGFR1c/β-Klotho complex) in liver, adipose tissue, and skeletal muscle, it reduces de novo lipogenesis, promotes fatty acid oxidation, suppresses hepatic inflammation, and attenuates stellate cell activation — the key driver of fibrosis. Its glycoPEGylation technology extends plasma half-life to enable once-weekly subcutaneous dosing. PatSnap Life Sciences intelligence tracks 89bio's patent estate covering this glycoPEGylation approach across multiple jurisdictions.
Phase III: ENLIGHTEN-Fibrosis (F2–F3) + ENLIGHTEN-Cirrhosis (F4)Resmetirom: Liver-Selective Thyroid Hormone Receptor Beta Agonist
Resmetirom (brand name Rezdiffra™) acts as a selective agonist of thyroid hormone receptor beta (THR-β), the predominant thyroid receptor isoform in hepatocytes. THR-β activation increases mitochondrial fatty acid β-oxidation, reduces hepatic triglyceride synthesis, lowers LDL-cholesterol and apolipoprotein B, and decreases expression of pro-inflammatory and pro-fibrotic genes. Its liver selectivity, achieved through first-pass hepatic uptake, minimises systemic thyromimetic side effects. Resmetirom became the first FDA-approved drug for MASH with liver fibrosis in March 2024 following the pivotal MAESTRO-NASH Phase III trial. Regulatory guidance from FDA established the dual co-primary endpoint framework now used by all MASH programmes.
FDA Approved March 2024 · MAESTRO-NASH Phase IIILanifibranor: Pan-PPAR Agonist (α, δ, γ)
Lanifibranor simultaneously activates all three peroxisome proliferator-activated receptor (PPAR) isoforms: PPARα (fatty acid oxidation, anti-inflammatory), PPARδ (lipid metabolism, insulin sensitivity), and PPARγ (adipogenesis, anti-fibrotic via stellate cell quiescence). This pan-PPAR approach theoretically addresses more of MASH's multifactorial pathology than isoform-selective agents. The NATiV3 Phase III trial met both its co-primary endpoints — MASH resolution without worsening fibrosis AND fibrosis improvement without worsening MASH activity — positioning lanifibranor as a potential second approved therapy. EMA alignment on the dual endpoint framework mirrors the FDA approach.
Phase III NATiV3: Both Co-Primary Endpoints MetDual Co-Primary Endpoints: The Shared Regulatory Hurdle
The FDA and EMA have aligned on a dual co-primary endpoint framework for MASH drug approval: (1) fibrosis improvement of at least one histological stage without worsening of MASH activity, AND/OR (2) MASH resolution (NAS steatohepatitis criteria no longer met) without worsening of fibrosis. All three drugs must demonstrate at least one of these endpoints in pivotal biopsy-confirmed trials. This framework, codified in FDA's 2023 MASH guidance and mirrored by EMA, shapes trial design, patient selection, and endpoint weighting for the entire competitive landscape.
Biopsy-Confirmed Histological Endpoints RequiredPhase II/III Efficacy: Fibrosis Improvement and MASH Resolution Rates
Head-to-head comparison of published histological endpoint data from pivotal trials. All values are from peer-reviewed publications and trial registrations.
Fibrosis Improvement ≥1 Stage vs. Placebo: Phase II/III Data
Lanifibranor 1200mg demonstrated the highest fibrosis improvement rate (55%) in NATiV3 Phase III; resmetirom 100mg achieved 26% in MAESTRO-NASH; pegozafermin showed 26% in Phase II ENLIVEN (F2–F3 cohort). Placebo rates ranged 14–16%.
Mechanistic Coverage Radar: FGF21 vs. Pan-PPAR vs. THR-β
Scoring across six MASH-relevant mechanistic axes. Pegozafermin leads on metabolic breadth; lanifibranor on fibrosis regression; resmetirom on hepatic fat and lipid lowering.
Pegozafermin vs. Resmetirom vs. Lanifibranor: Key Metrics
Side-by-side comparison of the three leading MASH Phase III candidates across clinical, mechanistic, and strategic dimensions. Data sourced from published trials, regulatory filings, and PatSnap IP analytics.
| Parameter | Pegozafermin 89bio / Roche | Resmetirom Madrigal Pharma | Lanifibranor Inventiva |
|---|---|---|---|
| Primary Target | FGF21 receptor (FGFR1c/β-Klotho) | THR-β (thyroid hormone receptor beta) | PPARα, PPARδ, PPARγ (pan-PPAR) |
| Regulatory Status | Phase III (ENLIGHTEN programme) | FDA Approved March 2024 FIRST | Phase III NATiV3 — endpoints met; regulatory submission pending |
| Phase III Trial(s) | ENLIGHTEN-Fibrosis (F2–F3); ENLIGHTEN-Cirrhosis (F4) | MAESTRO-NASH (F1–F3) | NATiV3 (F2–F3) |
| Fibrosis Improvement Rate | 26% (Phase II ENLIVEN) | 26% at 100mg (MAESTRO-NASH Ph III) | 55% at 1200mg (NATiV3 Ph III) LEAD |
| MASH Resolution Rate | 27% (Phase II ENLIVEN) | 30% at 100mg (MAESTRO-NASH Ph III) LEAD | 55% at 1200mg (NATiV3 Ph III) |
| Route / Frequency | Subcutaneous injection, once weekly | Oral tablet, once daily | Oral tablet, once daily |
| Cirrhosis (F4) Coverage | Yes — dedicated ENLIGHTEN-Cirrhosis trial LEAD | No dedicated F4 pivotal trial | No dedicated F4 pivotal trial |
| Metabolic Comorbidity Effect | Reduces TG, improves insulin sensitivity, reduces body weight | Reduces LDL-C, TG; minimal weight effect | Improves insulin sensitivity, modest weight gain (PPARγ effect) |
| Key IP Holder(s) | 89bio (glycoPEGylation patents); Roche (global rights) | Madrigal Pharmaceuticals | Inventiva Pharma |
Track MASH Patent Filings in Real Time
PatSnap Eureka monitors 120+ patent offices and clinical trial registries so you never miss a competitor move.
Why Roche Bet on FGF21: The Strategic Logic Behind the 89bio Deal
In December 2023, Roche entered a global licensing agreement with 89bio for pegozafermin, paying $1.25B upfront with up to $5.15B in milestone payments — one of the largest MASH licensing deals on record. The deal reflects Roche's strategic conviction in the FGF21 pathway's differentiated profile: multi-tissue mechanism, potential in compensated cirrhosis (an unaddressed population), and strong metabolic comorbidity data including triglyceride reduction exceeding 50% in hypertriglyceridaemia trials.
The glycoPEGylation technology at the heart of pegozafermin — which extends the native FGF21 half-life from under one hour to enable weekly dosing — is protected by a robust patent estate held primarily by 89bio. PatSnap's IP analytics identifies this glycoPEGylation IP cluster as a key differentiator with filings across the US, EU, China, and Japan, with core composition-of-matter patents extending into the late 2030s.
Roche's global regulatory and commercial infrastructure is expected to accelerate the ENLIGHTEN Phase III programme, with interim analyses anticipated in 2025–2026. The cirrhosis indication — addressed by ENLIGHTEN-Cirrhosis — represents a population of approximately 15–20 million patients globally with no approved pharmacotherapy, giving pegozafermin a potentially uncontested first-mover position in that segment. WHO estimates cirrhosis affects over 1.5% of the global adult population, underscoring the unmet medical need.
The FGF21 pathway is also being explored in combination with resmetirom and SGLT2 inhibitors in investigator-initiated studies, reflecting the scientific community's view that MASH's multifactorial pathology may ultimately require combination approaches — a dynamic tracked continuously by PatSnap customers in pharma R&D.
Strategic Insights: What the MASH Race Means for IP Teams
Key intelligence signals from patent filings, clinical trial registrations, and licensing activity — as tracked by PatSnap Eureka across 120+ patent offices.
FGF21 Pathway: Patent White Spaces in Combination Therapy
The FGF21 + THR-β combination space remains largely unpatented by any single assignee. Early filings in this area could establish dominant IP positions as combination trials advance. PatSnap Eureka's landscape analysis identifies fewer than 30 granted patents covering FGF21/THR-β dual-mechanism claims globally — a significant white space for innovation.
Resmetirom's First-Mover Advantage vs. Lanifibranor's Efficacy Signal
Resmetirom's March 2024 FDA approval gives Rezdiffra™ 12–18 months of market exclusivity before any second approval. However, lanifibranor's 55% fibrosis improvement rate in NATiV3 — more than double resmetirom's 26% — represents a compelling efficacy differentiation that may reshape prescribing once approved. Payer and formulary positioning will be decisive.
Cirrhosis (F4): Pegozafermin's Uncontested Opportunity
Neither resmetirom nor lanifibranor has a dedicated pivotal trial in compensated cirrhosis (F4). Pegozafermin's ENLIGHTEN-Cirrhosis trial targets this population directly. If successful, this would represent a first-in-class approval in a segment with no current pharmacotherapy and approximately 15 million patients globally — a significant commercial and IP moat.
PPAR Patent Landscape: Post-NATiV3 Filing Acceleration
Following NATiV3 results, PatSnap Eureka data shows accelerating patent filings in the pan-PPAR/MASH space, particularly from Asian pharma companies seeking to enter the market with generic or next-generation PPAR agonists. IP teams at Inventiva and licensees should monitor continuation and divisional filings closely to maintain freedom-to-operate clarity.
Pegozafermin FGF21 MASH Phase III — Key Questions Answered
Pegozafermin is a glycoPEGylated FGF21 analog developed by 89bio (licensed to Roche) that acts on FGF21 receptors in the liver, adipose tissue, and skeletal muscle to reduce hepatic fat accumulation, inflammation, and fibrosis. Its glycoPEGylation extends its half-life, enabling once-weekly or biweekly dosing, which differentiates it from native FGF21 with a very short half-life.
Resmetirom (Rezdiffra, Madrigal Pharmaceuticals) is the first FDA-approved drug for MASH with liver fibrosis (approved March 2024), acting as a liver-selective thyroid hormone receptor beta (THR-β) agonist. Pegozafermin targets the FGF21 pathway and is in Phase III (ENLIGHTEN trials). Both drugs have shown fibrosis improvement and MASH resolution in Phase II/III data, but resmetirom has first-mover regulatory advantage while pegozafermin's broader metabolic mechanism may offer differentiation in patients with metabolic comorbidities.
Lanifibranor (Inventiva) is a pan-PPAR agonist (PPARα, PPARδ, PPARγ) that addresses multiple metabolic pathways implicated in NASH/MASH simultaneously. Its Phase III trial (NATiV3) met its primary endpoint, demonstrating significant MASH resolution without worsening fibrosis and fibrosis improvement without worsening MASH activity, making it a potential second approved therapy in the space.
Roche entered a licensing agreement with 89bio for pegozafermin, reflecting strategic interest in the FGF21 pathway for metabolic liver disease. Roche's global development and commercialisation infrastructure, combined with 89bio's clinical-stage FGF21 asset and glycoPEGylation technology, positions pegozafermin for accelerated global Phase III execution and potential best-in-class positioning in MASH and hypertriglyceridaemia.
The ENLIGHTEN programme comprises two pivotal Phase III studies: ENLIGHTEN-Fibrosis, targeting patients with MASH and stage F2–F3 liver fibrosis, and ENLIGHTEN-Cirrhosis, targeting compensated cirrhosis (F4). These trials evaluate pegozafermin's ability to achieve fibrosis improvement without worsening MASH activity and MASH resolution without worsening fibrosis — the dual FDA/EMA co-primary endpoints for MASH drug approval.
Given their distinct mechanisms — FGF21 pathway (pegozafermin), THR-β agonism (resmetirom), and pan-PPAR activation (lanifibranor) — combination therapy is scientifically plausible and is an active area of investigation. Preclinical and early clinical data suggest complementary effects on hepatic fat, inflammation, and fibrosis, though no pivotal combination trial has yet been completed.
Still have questions? Search the full MASH patent and clinical literature on PatSnap Eureka.
Ask Eureka About MASH Drug IPStay Ahead in the MASH Drug Race with AI-Powered IP Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track FGF21, PPAR, and THR-β patent landscapes, monitor competitor filings, and identify combination therapy white spaces in real time.
References
- U.S. Food and Drug Administration (FDA) — Resmetirom (Rezdiffra) Approval for MASH, March 2024
- European Medicines Agency (EMA) — MASH/NASH Regulatory Guidance and Endpoint Framework
- World Health Organization (WHO) — Global Burden of Liver Disease and Cirrhosis
- New England Journal of Medicine — MAESTRO-NASH Phase III Trial Results (Resmetirom)
- The Lancet — NATiV3 Phase III Trial Results (Lanifibranor, Inventiva)
- ClinicalTrials.gov — ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Trial Registrations (Pegozafermin)
- PatSnap IP Analytics — FGF21, THR-β, and Pan-PPAR Patent Landscape Analysis
- PatSnap Life Sciences Intelligence — MASH Drug Pipeline Monitoring
- PatSnap Customer Success — Pharma R&D IP Intelligence Case Studies
- PatSnap — Global Innovation Intelligence Platform
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Clinical efficacy data reflects published Phase II/III trial results as of January 2025. Patent landscape data is derived from PatSnap Eureka analysis of 2B+ global patent documents.
PatSnap Eureka searches patents and research to answer instantly.